These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 12874157)

  • 1. Safety and immunoenhancing effect of a Chlorella-derived dietary supplement in healthy adults undergoing influenza vaccination: randomized, double-blind, placebo-controlled trial.
    Halperin SA; Smith B; Nolan C; Shay J; Kralovec J
    CMAJ; 2003 Jul; 169(2):111-7. PubMed ID: 12874157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
    Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.
    Hanania NA; Sockrider M; Castro M; Holbrook JT; Tonascia J; Wise R; Atmar RL;
    J Allergy Clin Immunol; 2004 Apr; 113(4):717-24. PubMed ID: 15100679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of a traditional Chinese medicine, Hochu-ekki-to, on antibody titer after influenza vaccination in man: a randomized, placebo-controlled, double-blind trial.
    Hamazaki K; Sawazaki S; Itomura M; Huan M; Shibahara N; Kawakita T; Kobayashi S; Hamazaki T
    Phytomedicine; 2007 Jan; 14(1):11-4. PubMed ID: 16644196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
    Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
    Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
    Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
    Webster A; Boyce M; Edmundson S; Miller I
    Clin Pharmacokinet; 1999; 36 Suppl 1():51-8. PubMed ID: 10429840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
    Falsey AR; Treanor JJ; Tornieporth N; Capellan J; Gorse GJ
    J Infect Dis; 2009 Jul; 200(2):172-80. PubMed ID: 19508159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of the immune response to influenza vaccine by acetylsalicylic acid: a clinical trial in a geriatric population.
    Hsia J; Tang T; Parrott M; Rogalla K
    Methods Find Exp Clin Pharmacol; 1994 Nov; 16(9):677-83. PubMed ID: 7746030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.